Evidence map›Paper›PMID 27743211›Full record

ArticleMolecular imaging and biology2017

Evaluation of a Flexible NOTA-RGD Kit Solution Using Gallium-68 from Different

Thomas Ebenhan, Isabel Schoeman, Daniel D Rossouw, Anne Grobler, Biljana Marjanovic-Painter, Judith Wagener, Hendrik G Kruger, Mike M Sathekge, Jan Rijn Zeevaart

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  2. Cold Kit Labeling: The Future ofFrontiers in medicine · 2022
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Thomas EbenhanNuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Isabel SchoemanDepartment of Science and Technology, Preclinical Drug Development Platform, North West University, Potchefstroom, South Africa.
Daniel D RossouwRadionuclide Production Department, iThemba LABS, Somerset West, South Africa.
Anne GroblerDepartment of Science and Technology, Preclinical Drug Development Platform, North West University, Potchefstroom, South Africa.
Biljana Marjanovic-PainterRadiochemistry, The South African Nuclear Energy Corporation SOC Ltd (Necsa), Pelindaba, Pretoria, South Africa.
Judith WagenerRadiochemistry, The South African Nuclear Energy Corporation SOC Ltd (Necsa), Pelindaba, Pretoria, South Africa.
Hendrik G KrugerCatalysis and Peptide Research Unit, University of KwaZulu Natal, Durban, South Africa.
Mike M SathekgeNuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Jan Rijn ZeevaartDepartment of Science and Technology, Preclinical Drug Development Platform, North West University, Potchefstroom, South Africa. janrijn.zeevaart@necsa.co.za.
North-West University · ZASouth African Nuclear Energy Corporation (South Africa) · ZAUniversity of Pretoria · ZAiThemba Laboratory · ZAUniversity of KwaZulu-Natal · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiopharmaceuticals containing the motive tripeptide arginyl-glycyl-asparatic acid (RGD) are known to target ανβ3 integrins during tumor angiogenesis. A more generic kit radiolabeling procedure accommodating Ga-68 from different generators was developed for NOTA-RGD and evaluated for its versatile use and safety in subsequent in vivo applications. The [ PROCEDURES: Single vial kits containing 28-56 nmol of NOTA-cyclo-Arg-Gly-Asp-d-Tyr-Lys (NOTA-RGD) and sodium acetate trihydrate buffer were formulated. Versatility of the NOTA-RGD radiolabeling performance and adaption to a TiO

resultsThe kits could be successfully formulated warranting integrity over 3-4 months with a good [

conclusionsA more versatile radiolabeling procedure using kit-formulated NOTA-RGD and different generator types was achieved. The uncompromised in vivo behavior and efficient targeting of SPN warrants further investigations on the clinical relevance of [

Indexed as

Diagnostic ImagingReagent Kits, DiagnosticAnimalsChlorocebus aethiopsFemaleGallium RadioisotopesHumansMaleMiddle AgedOligopeptidesPositron-Emission TomographySolitary Pulmonary NoduleSolutionsTissue DistributionTomography, X-Ray Computedarginyl-glycyl-aspartic acidGallium-68Gallium RadioisotopesOligopeptidesReagent Kits, DiagnosticSolutions[68Ga]AngiogenesisGallium-68Lung cancerNota-RGDPeptide radiolabelingPET/CT-imagingRGDανβ3-integrin

Identifiers

PMID27743211
OpenAlexW2530670224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.